Why ADMA Biologics, Inc.’s (ADMA) Stock Is Up 17.10%
As of Thursday, November 05, ADMA Biologics, Inc.’s ADMA share price has surged by 17.10%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Commentary & Analysis
Which Is a Better Investment, ADMA Biologics, Inc. or Vir Biotechnology, Inc. Stock?
Learn more about whether ADMA Biologics, Inc. or Vir Biotechnology, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, ADMA Biologics, Inc. or Xencor, Inc. Stock?
Learn more about whether ADMA Biologics, Inc. or Xencor, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Michael Rose
Why ADMA Biologics, Inc.’s (ADMA) Stock Is Up 5.66%
As of Wednesday, August 19, ADMA Biologics, Inc.’s ADMA share price has surged by 5.66%, which has investors questioning if this is right time to sell.Jenna Brashear
Is ADMA Biologics, Inc. (ADMA) Overvalued?
We dive into why ADMA Biologics, Inc. (ADMA) could be considered overvalued on 2026-08-05, based on AAII’s Value Score and Grade.Tudor Pop
Financial Summary
| Share Statistics | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,932.9 | $214.3 | 60% |
|
| Shares Out (Mil) | 225.8 | 53.9 | 78% |
|
| Institutional Ownership | 97.7% | 92.9% | 75% |
|
| Float (Mil) | 219.7 | 41.4 | 75% |
|
| Beta | 0.66 | 0.96 | 39% |
|
| Avg Daily Volume (000s) | 5,016 | 506 | 91% |
|
| Price Change (52-week) |
(9.6%) | 43.9% | 42% |
|
| Growth | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 64.6% | 13.2% | 97% |
|
| Net Income (5yr) | 31.6% | (10.1%) | 86% |
|
| EPS (5yr) | 21.8% | 15.8% | 71 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (15.7%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.197 | $0.797 | $0.943 | |
| Month Ago EPS | $0.197 | $0.797 | $0.943 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.197 | $0.797 | $0.983 | |
| Year/Year Chg | (10.5%) | 32.8% | 100.0% | |
| Financials | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $519 | $37 | 41% |
|
| Net Income (TTM) (Mil) | $182 | ($44) | 67% |
|
| EPS (TTM) | $0.788 | ($1.500) | 58% |
|
| Operating Cash Flow (TTM) (Mil) | $141 | ($34) | 55% |
|
| Net Cash Flow (TTM) (Mil) | $63 | $1 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $197 | $4 | 50% |
|
| Enterprise Value (Q1) (Mil) | $2,426 | $172 | 52% |
|
| Valuation | ADMA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.71 | 2.00 | 87% |
|
| P/E | 17.1 | 18.5 | 45% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.8 | 0.9 | 39% |
|
| Ratios | ADMA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.5% | 67.3% | 80% |
|
| Net Margin | 35.1% | (63.5%) | 92% |
|
| ROA | 28.0% | (47.5%) | 98% |
|
| ROE | 41.9% | (53.3%) | 91% |
|
| Liabilities to Assets | 40.1% | 29.6% | 31% |
|
| F-Score | 4 | 2 | 33% |
|
ADMA Biologics, Inc. did not pass any screens on 11/5/2026.
